v3.25.1
Segment Reporting (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Segment Reporting Information [Line Items]    
Total revenue $ 93,881 $ 70,502
Cost of revenue from sale of therapies (831) (246)
R&D expenses (56,468) (57,459)
SG&A expenses (40,198) (39,287)
Net income (loss) 5,023 (24,436)
Reportable segment    
Segment Reporting Information [Line Items]    
Total revenue 93,881 70,502
Cost of revenue from sale of therapies (831) (246)
Other segment expense, net (6,163) (11,296)
Net income (loss) 5,023 (24,436)
Reportable segment | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (37,931) (41,339)
Reportable segment | PRAME programs | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (17,305) (26,700)
Reportable segment | Tebentafusp programs | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (7,990) (5,894)
Reportable segment | Infectious disease programs | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (1,405) (2,246)
Reportable segment | All other external clinical and preclinical costs | External R&D    
Segment Reporting Information [Line Items]    
R&D expenses (11,231) (6,499)
Reportable segment | Salaries and other employee related cost    
Segment Reporting Information [Line Items]    
R&D expenses (11,043) (9,754)
SG&A expenses (12,218) (14,840)
Reportable segment | Other SG&A expenses    
Segment Reporting Information [Line Items]    
SG&A expenses $ (20,672) $ (17,463)